Compare ARDX & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | NNNN |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | NNNN |
|---|---|---|
| Price | $5.71 | $21.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $15.14 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 39.2K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $38.22 | N/A |
| Revenue Next Year | $33.85 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.50 | $5.91 |
| 52 Week High | $8.40 | $55.65 |
| Indicator | ARDX | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 46.39 |
| Support Level | $5.49 | $22.08 |
| Resistance Level | $6.23 | $31.44 |
| Average True Range (ATR) | 0.31 | 2.34 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 13.41 | 24.42 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.